BR112017009671A2 - inibidores de ezh2 e usos destes - Google Patents
inibidores de ezh2 e usos destesInfo
- Publication number
- BR112017009671A2 BR112017009671A2 BR112017009671A BR112017009671A BR112017009671A2 BR 112017009671 A2 BR112017009671 A2 BR 112017009671A2 BR 112017009671 A BR112017009671 A BR 112017009671A BR 112017009671 A BR112017009671 A BR 112017009671A BR 112017009671 A2 BR112017009671 A2 BR 112017009671A2
- Authority
- BR
- Brazil
- Prior art keywords
- ezh2
- inhibitors
- ezh1
- homologous
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Abstract
a presente descrição proporciona compostos de qualquer uma das fórmulas (i) e (ii). os compostos aqui descritos são inibidores de histonas metiltransferases (e.g., potenciador de zeste homólogo 1 (ezh1) e intensificador de zeste homólogo 2 (ezh2)) são úteis no tratamento e / ou prevenção de uma ampla gama de doenças (por exemplo, doenças proliferativas). a presente invenção também fornece composições farmacêuticas, kits, métodos, e usos incluindo ou usando um composto descrito aqui. ademais, também é fornecido são métodos de identificação de inibidores de ezh1 e/ou ezh2. (i) (ii)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462076410P | 2014-11-06 | 2014-11-06 | |
PCT/US2015/059622 WO2016073956A1 (en) | 2014-11-06 | 2015-11-06 | Ezh2 inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017009671A2 true BR112017009671A2 (pt) | 2017-12-26 |
Family
ID=55909933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017009671A BR112017009671A2 (pt) | 2014-11-06 | 2015-11-06 | inibidores de ezh2 e usos destes |
Country Status (8)
Country | Link |
---|---|
US (1) | US11236082B2 (pt) |
EP (2) | EP3214935A4 (pt) |
KR (1) | KR20170081213A (pt) |
CN (1) | CN107105651A (pt) |
AU (1) | AU2015342774C1 (pt) |
BR (1) | BR112017009671A2 (pt) |
CA (1) | CA2964629A1 (pt) |
WO (1) | WO2016073956A1 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11819554B2 (en) * | 2015-09-17 | 2023-11-21 | University Of Massachusetts | Compositions and methods for modulating FMR1 expression |
EP3445365A4 (en) | 2016-04-22 | 2019-10-16 | Dana-Farber Cancer Institute, Inc. | EZH2 INHIBITORS AND USES THEREOF |
WO2018076060A1 (en) | 2016-10-26 | 2018-05-03 | Genea Ip Holdings Pty Ltd | Improved generation of muscle lineage cells and therapeutic uses thereof |
CA3041840A1 (en) * | 2016-10-28 | 2018-05-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
EP3538102A4 (en) | 2016-11-10 | 2020-06-24 | Memorial Sloan-Kettering Cancer Center | INHIBITATION OF KMT2D FOR TREATING CANCER |
US11541051B2 (en) | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
WO2018135556A1 (ja) | 2017-01-19 | 2018-07-26 | 第一三共株式会社 | Htlv-1関連脊髄症を治療することに用いるための医薬組成物 |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
EP3612181A4 (en) | 2017-04-21 | 2021-01-06 | Epizyme, Inc. | COMBINATION THERAPIES WITH EHMT2 INHIBITORS |
AU2018353139A1 (en) * | 2017-10-18 | 2020-06-04 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in immunotherapies |
CN112004816B (zh) | 2018-01-31 | 2024-01-05 | 米拉蒂医疗股份有限公司 | Prc2抑制剂 |
CN110229151B (zh) * | 2018-03-06 | 2021-09-10 | 上海海和药物研究开发股份有限公司 | 吲嗪类化合物、其制备方法及用途 |
CN112154146A (zh) | 2018-03-06 | 2020-12-29 | 西奈山伊坎医学院 | 丝氨酸苏氨酸激酶(akt)降解/破坏化合物和使用方法 |
CA3104209A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
CN109966479A (zh) * | 2019-02-26 | 2019-07-05 | 上海长征医院 | Ezh2在制备预防或治疗多囊肾病药物中的应用 |
EP3976044A1 (en) * | 2019-06-03 | 2022-04-06 | Icahn School of Medicine at Mount Sinai | Compounds and methods for inhibiting cancers via rest inhibition |
CN112341390B (zh) * | 2019-08-07 | 2022-08-23 | 四川大学 | 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途 |
EP3797777A1 (en) | 2019-09-30 | 2021-03-31 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Agent for the treatment of psoriasis |
CN111303133A (zh) * | 2020-03-25 | 2020-06-19 | 清华大学 | 降解ezh2蛋白的小分子化合物 |
WO2022042527A1 (zh) * | 2020-08-24 | 2022-03-03 | 北京大学 | 治疗内耳及肠道上皮组织损伤相关疾病的小分子药物 |
CN112715484B (zh) * | 2020-12-29 | 2022-04-22 | 四川省人民医院 | 构建视网膜色素变性疾病模型的方法、应用以及繁育方法 |
CN114028397A (zh) * | 2021-02-01 | 2022-02-11 | 徐州医科大学 | Gsk126作为ezh2抑制剂在制备预防和/或治疗缺血性脑卒中药物中的应用 |
CN113736728B (zh) * | 2021-08-20 | 2024-03-08 | 内蒙古大学 | 一种小鼠体细胞核移植胚胎培养液及胚胎培养方法 |
TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4658649A (en) | 1985-06-06 | 1987-04-21 | Combustion Engineering, Inc. | Ultrasonic method and device for detecting and measuring defects in metal media |
US8338464B2 (en) | 2006-11-30 | 2012-12-25 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of BCL6 |
KR20080107050A (ko) | 2007-06-05 | 2008-12-10 | 울산대학교 산학협력단 | 항-cd137 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
US8791075B2 (en) | 2008-06-24 | 2014-07-29 | Albert Einstein College Of Medicine Of Yeshiva University | Methods and compositions for inhibition of BCL6 repression |
US8637509B2 (en) * | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
ES2534804T3 (es) * | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
JP5864545B2 (ja) * | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | インドール |
MX362384B (es) | 2010-05-14 | 2019-01-15 | Dana Farber Cancer Inst Inc | Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
US20120014979A1 (en) | 2010-07-16 | 2012-01-19 | Alexander Dent | Use of bcl6 inhibitors for treating autoimmune diseases |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
KR102061353B1 (ko) | 2010-09-10 | 2020-01-02 | 에피자임, 인코포레이티드 | 인간 ezh2의 억제제 및 이의 사용 방법 |
AU2012223448B2 (en) * | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
ES2624986T3 (es) * | 2011-09-13 | 2017-07-18 | Glaxosmithkline Llc | Azaindazoles |
RU2014117632A (ru) | 2011-09-30 | 2015-11-10 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Способы лечения злокачественной опухоли |
CA2854447A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
CN109529026A (zh) | 2012-02-17 | 2019-03-29 | 安迅生物制药公司 | 用于治疗流感和副流感患者的方法、化合物和组合物 |
TR201904660T4 (tr) | 2012-03-12 | 2019-05-21 | Epizyme Inc | İnsan EZH2 inhibitörleri ve bunun kullanım yöntemleri. |
US10301290B2 (en) | 2012-04-13 | 2019-05-28 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
EP2934531A4 (en) | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
US20150344427A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | 1,4-pyridone compounds |
CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
WO2014155301A1 (en) * | 2013-03-26 | 2014-10-02 | Piramal Enterprises Limited | Substituted bicyclic compounds as inhibitors of ezh2 |
EP3022184B1 (en) | 2013-07-19 | 2017-09-27 | Epizyme, Inc. | Substituted benzene compounds |
WO2015077193A1 (en) | 2013-11-19 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
WO2015110999A1 (en) | 2014-01-24 | 2015-07-30 | Piramal Enterprises Limited | Ezh2 inhibitors and uses thereof |
CN107249593A (zh) | 2014-11-06 | 2017-10-13 | 达纳-法伯癌症研究所股份有限公司 | 调节染色质结构的组合物用于移植物抗宿主疾病(gvhd)的用途 |
EP3445365A4 (en) | 2016-04-22 | 2019-10-16 | Dana-Farber Cancer Institute, Inc. | EZH2 INHIBITORS AND USES THEREOF |
-
2015
- 2015-11-06 EP EP15857195.0A patent/EP3214935A4/en not_active Withdrawn
- 2015-11-06 WO PCT/US2015/059622 patent/WO2016073956A1/en active Application Filing
- 2015-11-06 KR KR1020177014970A patent/KR20170081213A/ko not_active Application Discontinuation
- 2015-11-06 CN CN201580072658.6A patent/CN107105651A/zh active Pending
- 2015-11-06 US US15/524,679 patent/US11236082B2/en active Active
- 2015-11-06 AU AU2015342774A patent/AU2015342774C1/en active Active
- 2015-11-06 EP EP21171598.2A patent/EP3885343A1/en not_active Withdrawn
- 2015-11-06 BR BR112017009671A patent/BR112017009671A2/pt not_active Application Discontinuation
- 2015-11-06 CA CA2964629A patent/CA2964629A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3214935A4 (en) | 2018-08-29 |
WO2016073956A1 (en) | 2016-05-12 |
EP3214935A1 (en) | 2017-09-13 |
KR20170081213A (ko) | 2017-07-11 |
CN107105651A (zh) | 2017-08-29 |
AU2015342774C1 (en) | 2021-08-05 |
AU2015342774A1 (en) | 2017-04-27 |
EP3885343A1 (en) | 2021-09-29 |
CN113444086A (zh) | 2021-09-28 |
US11236082B2 (en) | 2022-02-01 |
AU2015342774B2 (en) | 2020-01-30 |
US20180297993A1 (en) | 2018-10-18 |
CA2964629A1 (en) | 2016-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017009671A2 (pt) | inibidores de ezh2 e usos destes | |
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
CY1120361T1 (el) | Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido) | |
CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
GT201600215A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
BR112016028255A2 (pt) | agentes imunorreguladores | |
EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
EA201790108A1 (ru) | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента | |
EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
EA201790806A1 (ru) | Иммунорегулирующие средства | |
EA201790992A1 (ru) | Иммунорегуляторные агенты | |
CU24389B1 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
BR112016029846A2 (pt) | ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo? | |
BR112016028818A2 (pt) | composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo. | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
CY1122364T1 (el) | Αναστολεις της ezh2 | |
EA201692483A1 (ru) | Ингибиторы гистоновой метилазы | |
ZA201904522B (en) | Heterocyclic inhibitors of mct4 | |
BR112017013568A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |